Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 11, 2023. (Total: 223939Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 11 (of 11 Records)

Query Trace: Vomiting and BID[original query]
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
American journal of hematology 2015 Apr 90 (4): 276-81.
Strati Paolo, Kantarjian Hagop, Ravandi Farhad, Nazha Aziz, Borthakur Gautam, Daver Naval, Kadia Tapan, Estrov Zeev, Garcia-Manero Guillermo, Konopleva Marina, Rajkhowa Trivikram, Durand Menda, Andreeff Michael, Levis Mark, Cortes Jor
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91.
Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecologic oncology 2017 9 147 (2): 267-275.
Oza Amit M, Tinker Anna V, Oaknin Ana, Shapira-Frommer Ronnie, McNeish Iain A, Swisher Elizabeth M, Ray-Coquard Isabelle, Bell-McGuinn Katherine, Coleman Robert L, O'Malley David M, Leary Alexandra, Chen Lee-May, Provencher Diane, Ma Ling, Brenton James D, Konecny Gottfried E, Castro Cesar M, Giordano Heidi, Maloney Lara, Goble Sandra, Lin Kevin K, Sun James, Raponi Mitch, Rolfe Lindsey, Kristeleit Rebecca
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
The journal of prevention of Alzheimer's disease 2017 4 (3): 149-156.
Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey J A, Power A, Wang P, Shen L, Tolar
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Cancer medicine 2018 May .
Werner Theresa L, Sachdev Jasgit, Swisher Elizabeth M, Gutierrez Martin, Kittaneh Muaiad, Stein Mark N, Xiong Hao, Dunbar Martin, Sullivan Danielle, Komarnitsky Philip, McKee Mark, Tan Antoinette
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
British journal of cancer 2018 12 120 (3): 286-293.
de Weger Vincent A, de Jonge Maja, Langenberg Marlies H G, Schellens Jan H M, Lolkema Martijn, Varga Andrea, Demers Brigitte, Thomas Koruth, Hsu Karl, Tuffal Gilles, Goodstal Samantha, Macé Sandrine, Deutsch Er
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
The oncologist 2020 12 26 (4): 290-e545.
van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Investigational new drugs 2021 Mar .
Zauderer Marjorie G, Alley Evan W, Bendell Johanna, Capelletto Enrica, Bauer Todd M, Callies Sophie, Szpurka Anna M, Kang Suhyun, Willard Melinda D, Wacheck Volker, Varghese Anna
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
Scientific reports 2021 2 11 (1): 4433.
Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249.
Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: ?Safety, Efficacy, and Biomarkers.
The oncologist 2022 4 27 (5): 342-e383.
Wang Yakun, Liu Tianshu, Chen Gongyan, Gong Jifang, Bai Yuxian, Zhang Tao, Xu Nong, Liu Li, Xu Jianming, He Jianxing, Liu Yunpeng, Zhang Li, Jiang Da, Wang Mengzhao, Chang Jianhua, Li Wei, Bai Chunmei, Zhou Jinghong, Wang Jian, Ren Yongxin, Zhang Liya, Su Weiguo, Liu Baorui, Shen L
TOP